Cargando…
Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review
Diabetic retinopathy (DR) is classically defined by its vascular lesions and damage in the neurons of the retina. The cellular and clinical elements of DR have many features of chronic inflammation. Understanding the individual cell-specific inflammatory changes in the retina may lead to novel thera...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5822768/ https://www.ncbi.nlm.nih.gov/pubmed/29576875 http://dx.doi.org/10.1155/2018/1694187 |
_version_ | 1783301748346060800 |
---|---|
author | Lu, Lei Jiang, Ying Jaganathan, Ravindran Hao, Yanli |
author_facet | Lu, Lei Jiang, Ying Jaganathan, Ravindran Hao, Yanli |
author_sort | Lu, Lei |
collection | PubMed |
description | Diabetic retinopathy (DR) is classically defined by its vascular lesions and damage in the neurons of the retina. The cellular and clinical elements of DR have many features of chronic inflammation. Understanding the individual cell-specific inflammatory changes in the retina may lead to novel therapeutic approaches to prevent vision loss. The systematic use of available pharmacotherapy has been reported as a useful adjunct tool to laser photocoagulation, a gold standard therapy for DR. Direct injections or intravitreal anti-inflammatory and antiangiogenesis agents are widely used pharmacotherapy to effectively treat DR and diabetic macular edema (DME). However, their effectiveness is short term, and the delivery system is often associated with adverse effects, such as cataract and increased intraocular pressure. Further, systemic agents (particularly hypoglycemic, hypolipidemic, and antihypertensive agents) and plants-based drugs have also provided promising treatment in the progression of DR. Recently, advancements in pluripotent stem cells technology enable restoration of retinal functionalities after transplantation of these cells into animals with retinal degeneration. This review paper summarizes the developments in the current and potential pharmacotherapy and therapeutic technology of DR. Literature search was done on online databases, PubMed, Google Scholar, clinitrials.gov, and browsing through individual ophthalmology journals and leading pharmaceutical company websites. |
format | Online Article Text |
id | pubmed-5822768 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-58227682018-03-25 Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review Lu, Lei Jiang, Ying Jaganathan, Ravindran Hao, Yanli J Ophthalmol Review Article Diabetic retinopathy (DR) is classically defined by its vascular lesions and damage in the neurons of the retina. The cellular and clinical elements of DR have many features of chronic inflammation. Understanding the individual cell-specific inflammatory changes in the retina may lead to novel therapeutic approaches to prevent vision loss. The systematic use of available pharmacotherapy has been reported as a useful adjunct tool to laser photocoagulation, a gold standard therapy for DR. Direct injections or intravitreal anti-inflammatory and antiangiogenesis agents are widely used pharmacotherapy to effectively treat DR and diabetic macular edema (DME). However, their effectiveness is short term, and the delivery system is often associated with adverse effects, such as cataract and increased intraocular pressure. Further, systemic agents (particularly hypoglycemic, hypolipidemic, and antihypertensive agents) and plants-based drugs have also provided promising treatment in the progression of DR. Recently, advancements in pluripotent stem cells technology enable restoration of retinal functionalities after transplantation of these cells into animals with retinal degeneration. This review paper summarizes the developments in the current and potential pharmacotherapy and therapeutic technology of DR. Literature search was done on online databases, PubMed, Google Scholar, clinitrials.gov, and browsing through individual ophthalmology journals and leading pharmaceutical company websites. Hindawi 2018-01-17 /pmc/articles/PMC5822768/ /pubmed/29576875 http://dx.doi.org/10.1155/2018/1694187 Text en Copyright © 2018 Lei Lu et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Lu, Lei Jiang, Ying Jaganathan, Ravindran Hao, Yanli Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review |
title | Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review |
title_full | Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review |
title_fullStr | Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review |
title_full_unstemmed | Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review |
title_short | Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review |
title_sort | current advances in pharmacotherapy and technology for diabetic retinopathy: a systematic review |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5822768/ https://www.ncbi.nlm.nih.gov/pubmed/29576875 http://dx.doi.org/10.1155/2018/1694187 |
work_keys_str_mv | AT lulei currentadvancesinpharmacotherapyandtechnologyfordiabeticretinopathyasystematicreview AT jiangying currentadvancesinpharmacotherapyandtechnologyfordiabeticretinopathyasystematicreview AT jaganathanravindran currentadvancesinpharmacotherapyandtechnologyfordiabeticretinopathyasystematicreview AT haoyanli currentadvancesinpharmacotherapyandtechnologyfordiabeticretinopathyasystematicreview |